Libotryp XL 25 Tablet is a combination pharmaceutical formulation containing Amitriptyline 25 mg and Chlordiazepoxide 10 mg, primarily indicated for the management of anxiety associated with depression and certain psychosomatic disorders. Amitriptyline, a tricyclic antidepressant, exerts its therapeutic effects by inhibiting the reuptake of norepinephrine and serotonin, thereby enhancing neurotransmitter activity in the central nervous system to alleviate depressive symptoms. Chlordiazepoxide, a benzodiazepine derivative, provides anxiolytic, sedative, and muscle-relaxant properties through potentiation of gamma-aminobutyric acid (GABA) neurotransmission. The synergistic action of these agents facilitates effective relief from anxiety, tension, and depressive mood states. Libotryp XL 25 is typically prescribed for short-term use under medical supervision due to the potential for dependence associated with benzodiazepines. Dosage should be individualized based on clinical response and tolerability, with caution advised in patients with a history of substance abuse, hepatic or renal impairment, and elderly populations. Common adverse effects may include drowsiness, dry mouth, dizziness, and gastrointestinal disturbances. Patients should avoid alcohol consumption during therapy. This medication should be used strictly as directed by a healthcare professional, with regular monitoring to optimize therapeutic outcomes and minimize risks.